Figure 3.

GETAID vedolizumab cohort treatment outcomes stratified by CDST. (A) Treatment outcomes stratified by CDST in overall GETAID cohort. (B) Treatment outcomes stratified by CDST in GETAID cohort on Q8 week vedolizumab maintenance. (C) Reduction in HBI stratified by CDST. (D) Reduction in HBI after vedolizumab interval shortening (escalation) stratified by CDST. Low probability; ≤13 points in CDST model at baseline. Intermediate probability; >13 to ≤19 in CDST model at baseline. High probability; >19 points in CDST model at baseline. *P < 0.05. Abbreviations: CDST, clinical decision support tool; HBI, Harvey‐Bradshaw index; Q8, every 8 weeks; REM, remission; SF‐REM, steroid‐free remission. High‐probability group (n = 3); intermediate‐probability group (n = 24); low‐probability group (n = 28). Because of the small sample size of the high‐probability group (a highly refractory population early in the period during which vedolizumab became available), it was combined with the intermediate‐probability group for analyses